Watchlist Price Alert

Glaukos Corporation (GKOS)

NYSE: GKOS · Real-Time Price · USD

96.20

-0.99 (-1.02%)

At close: May 23, 2025, 3:59 PM

94.04

-2.25%

After-hours: May 23, 2025, 05:39 PM EDT

-1.02% (1D)

Bid	91.21
Market Cap	5.5B
Revenue (ttm)	404.52M
Net Income (ttm)	-123.68M
EPS (ttm)	-2.27
PE Ratio (ttm)	-42.38
Forward PE	3244.67
Analyst	Buy

Ask	94.64
Volume	577,333
Avg. Volume (20D)	1,069,863
Open	94.78
Previous Close	97.19
Day's Range	94.64 - 96.82
52-Week Range	77.10 - 163.71
Beta	0.83

About GKOS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GKOS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for GKOS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

-11.36%

Glaukos shares are trading lower after the company... Unlock content with Pro Subscription

3 months ago

-20.01%

Glaukos shares are trading lower after the company reported Q4 Adj Eps miss.

News

3 days ago · zacks.com

Here's Why You Should Retain Glaukos Stock in Your Portfolio

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

3 weeks ago · zacks.com

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimate...

3 weeks ago · zacks.com

GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline

Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.

3 weeks ago · seekingalpha.com

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Glaukos Corporation (NYSE:GKOS ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations and Corporate Affairs Tom Burns - Ch...

3 weeks ago · zacks.com

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.70 per share a year ago.

3 weeks ago · businesswire.com

Glaukos Announces First Quarter 2025 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

3 weeks ago · seekingalpha.com

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

1 month ago · zacks.com

Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.